期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 10, 期 12, 页码 1917-1932出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.10.182
关键词
bladder cancer; targeted therapy; transitional cell carcinoma; urothelial cancer
类别
资金
- NCI NIH HHS [T32 CA009207, T32 CA009207-35, R25 CA020449] Funding Source: Medline
Advanced urothelial cancer is associated with a poor prognosis and there has been no substantial progress over the past three decades since the development of platinum-based multiagent chemotherapy. Clinical trials evaluating novel agents and combinations including chemotherapeutic drugs, as well as targeted inhibitors, are desperately needed. With a better understanding of the complex molecular alterations that drive urothelial tumorigenesis, new targets for novel therapeutics are being defined. This article will describe the current state of advanced urothelial cancer treatment and provide a comprehensive discussion of novel agents in development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据